Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639834 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00639834 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 26 participants.
The verdict
NCT00639834, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if MDX-1342 given in combination with Methotrexate is a safe treatment for patients with active rheumatoid arthritis. In addition, changes in the severity patients' arthritis will also be analysed.
Interventions
- BIOLOGICAL MDX-1342
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639834
The ClinicalTrials.gov registry entry for NCT00639834 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-1342 is the first listed.
NCT00639834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639834 about?
NCT00639834 is a clinical study titled "Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis". The purpose of this study is to determine if MDX-1342 given in combination with Methotrexate is a safe treatment for patients with active rheumatoid arthritis. In addition, changes in the severity patients' arthritis will also be analysed.
What is the current status of trial NCT00639834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00639834?
The interventions under investigation include: MDX-1342 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00639834?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.